Tadaaki Yamada

List of Publications by Year in Descending Order

129 papers	2,646 citations	30 h-index	48 g-index
156 ext. papers	3,256 ext. citations	5.6 avg, IF	4.67 L-index

#	Paper	IF	Citations
129	Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells.. *Cancer Medicine*, **2022**,	4.8	2
128	HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.. *Npj Precision Oncology*, **2022**, 6, 5	9.8	0
127	Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer.. *Diagnostics*, **2022**, 12,	3.8	3
126	A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma.. *Translational Lung Cancer Research*, **2022**, 11, 238-249	4.4	0
125	A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors.. *International Immunopharmacology*, **2022**, 108, 108775	5.8	0
124	Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients. *Journal of Cancer Research and Clinical Oncology*, **2021**, 1	4.9	0
123	Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study. *Thoracic Cancer*, **2021**, 13, 173	3.2	1
122	TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection. *Applied Immunohistochemistry and Molecular Morphology*, **2021**, 29, 313-320	1.9	2
121	Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study. *Frontiers in Oncology*, **2021**, 11, 630136	5.3	3
120	Plasma membrane anchored nanosensor for quantifying endogenous production of HO in living cells. *Biosensors and Bioelectronics*, **2021**, 179, 113077	11.8	5
119	The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study. *Frontiers in Oncology*, **2021**, 11, 663612	5.3	4
118	Androgen replacement therapy for cancer-related symptoms in male: result of prospective randomized trial (ARTFORM study). *Journal of Cachexia, Sarcopenia and Muscle*, **2021**, 12, 831-842	10.3	2
117	TGF-□dependent reprogramming of amino acid metabolism induces epithelial-mesenchymal transition in non-small cell lung cancers. *Communications Biology*, **2021**, 4, 782	6.7	5
116	Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. *OncoImmunology*, **2021**, 10, 1950411	7.2	5
115	Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab. *Internal Medicine*, **2021**, 60, 3585-3588	1.1	1
114	Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study. *Translational Lung Cancer Research*, **2021**, 10, 193-201	4.4	0
113	Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated -mutated advanced non-small cell lung cancer: a prospective observational study. *Translational Lung Cancer Research*, **2021**, 10, 3582-3593	4.4	1

112	Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study. *Journal of Cancer Research and Clinical Oncology*, **2021**, 1	4.9	0
111	Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. *Lung Cancer*, **2021**, 161, 26-33	5.9	6
110	Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer. *Cancer Letters*, **2021**, 522, 119-128	9.9	3
109	Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. *Journal of Clinical Medicine*, **2020**, 9,	5.1	45
108	Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801. *Oncologist*, **2020**, 25, e1146-e1157	5.7	
107	Respiratory complications of Stevens-Johnson syndrome (SJS): 3 cases of SJS-induced obstructive bronchiolitis. *Allergology International*, **2020**, 69, 465-467	4.4	1
106	Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
105	Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study). *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835920927841	5.4	6
104	Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review. *Journal of Clinical Medicine*, **2020**, 9,	5.1	5
103	ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in -Mutated Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2020**, 26, 2244-2256	12.9	36
102	The Quality of Life of Patients with Suspected Lung Cancer before and after Bronchoscopy and the Effect of Mirtazapine on the Depressive Status. *Internal Medicine*, **2020**, 59, 1605-1610	1.1	1
101	Histone deacetylase inhibitor OBP-801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1-dependent apoptosis. *International Journal of Oncology*, **2020**, 56, 848-856	4.4	1
100	Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer. *Oncologist*, **2020**, 25, 208-e417	5.7	2
99	Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients. *Scientific Reports*, **2020**, 10, 17495	4.9	6
98	Association of immune checkpoint inhibitors with respiratory infections: A review. *Cancer Treatment Reviews*, **2020**, 90, 102109	14.4	1
97	Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients. *Medical Oncology*, **2020**, 37, 111	3.7	2
96	Diverse Receptor Tyrosine Kinase Phosphorylation in Urine-Derived Tubular Epithelial Cells from Autosomal Dominant Polycystic Kidney Disease Patients. *Nephron*, **2020**, 144, 525-536	3.3	
95	Advanced G-CSF-producing non-small cell lung cancer-not otherwise specified, with favourable response to pembrolizumab monotherapy. *Respirology Case Reports*, **2020**, 8, e00625	0.9	1

94	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. *Nature Communications*, **2020**, 11, 4607	17.4	31
93	Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer. *Lung Cancer*, **2019**, 137, 108-112	5.9	9
92	Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. *Translational Lung Cancer Research*, **2019**, 8, 450-460	4.4	8
91	Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis. *Thoracic Cancer*, **2019**, 10, 557-563	3.2	3
90	Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer. *Thoracic Cancer*, **2019**, 10, 526-532	3.2	7
89	Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial. *Oncologist*, **2019**, 24, 593-e170	5.7	8
88	The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2019**, 14, 1061-1076	8.9	12
87	Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer. *Oncologist*, **2019**, 24, 1033-e617	5.7	3
86	Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. *Cancers*, **2019**, 11,	6.6	8
85	Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients. *Cancers*, **2019**, 11,	6.6	7
84	Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions. *Cancers*, **2019**, 11,	6.6	15
83	Tumor Neovascularization and Developments in Therapeutics. *Cancers*, **2019**, 11,	6.6	46
82	Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study). *Clinical Lung Cancer*, **2019**, 20, e402-e406	4.9	5
81	Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. *Journal of Clinical Medicine*, **2019**, 8,	5.1	49
80	Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. *Molecular Cancer Therapeutics*, **2019**, 18, 947-956	6.1	9
79	Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. *Cancer Medicine*, **2019**, 8, 1521-1529	4.8	41
78	Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of Mutation Status. *Cancer Research*, **2019**, 79, 1658-1670	10.1	44
77	Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. *Investigational New Drugs*, **2019**, 37, 291-296	4.3	4

76	Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer. *Translational Lung Cancer Research*, **2019**, 8, 227-234	4.4	10
75	Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study). *Translational Lung Cancer Research*, **2019**, 8, 519-523	4.4	
74	The Impact of Immune-related Adverse Events on the Effect of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. *Japanese Journal of Lung Cancer*, **2019**, 59, 128-136	0.1	2
73	Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. *Journal of Clinical Medicine*, **2019**, 9,	5.1	26
72	The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer. *Translational Lung Cancer Research*, **2019**, 8, 847-853	4.4	24
71	Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study). *Translational Lung Cancer Research*, **2019**, 8, 1086-1090	4.4	3
70	A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer. *Oncologist*, **2019**, 24, 459-e131	5.7	2
69	AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. *Nature Communications*, **2019**, 10, 259	17.4	116
68	Foretinib Overcomes Entrectinib Resistance Associated with the G667C Mutation in Fusion-Positive Tumor Cells in a Brain Metastasis Model. *Clinical Cancer Research*, **2018**, 24, 2357-2369	12.9	17
67	Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring Mutations. *Molecular Cancer Therapeutics*, **2018**, 17, 17-25	6.1	19
66	Notch3-dependent □catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. *Nature Communications*, **2018**, 9, 3198	17.4	33
65	Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy na□e patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial. *Investigational New Drugs*, **2018**, 36, 903-910	4.3	5
64	Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment. *Medicine (United States)*, **2018**, 97, e11081	1.8	5
63	Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non-small cell lung cancer with brain metastasis. *Medicine (United States)*, **2018**, 97, e11084	1.8	5
62	Effective combined therapy with ramucirumab for advanced pulmonary pleomorphic carcinoma. *Respirology Case Reports*, **2018**, 6, e00372	0.9	1
61	Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report. *BMC Pulmonary Medicine*, **2018**, 18, 193	3.5	6
60	The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations. *BMC Cancer*, **2018**, 18, 1241	4.8	1
59	Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report. *Respiratory Medicine Case Reports*, **2018**, 25, 261-263	1.2	5

58	An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer. *Medicine (United States)*, **2018**, 97, e12660	1.8	
57	Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors. *Cancer Science*, **2017**, 108, 53-60	6.9	20
56	Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of -mutant Lung Cancer. *Molecular Cancer Therapeutics*, **2017**, 16, 506-515	6.1	35
55	A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab. *European Journal of Dermatology*, **2017**, 27, 193-194	0.8	10
54	Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation. *Cancer Science*, **2017**, 108, 696-703	6.9	9
53	Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway. *Cancer Science*, **2017**, 108, 1378-1385	6.9	13
52	Histone Deacetylase 3 Inhibition Overcomes Deletion Polymorphism-Mediated Osimertinib Resistance in Mutant Lung Cancer. *Clinical Cancer Research*, **2017**, 23, 3139-3149	12.9	52
51	In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs. *Cancer Medicine*, **2017**, 6, 2972-2983	4.8	1
50	A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma. *Cancer Research*, **2017**, 77, 153-163	10.1	18
49	Androgen replacement therapy for cancer-related symptoms in male advanced cancer patients: study protocol for a randomised prospective trial (ARTFORM study). *Journal of Medical Investigation*, **2017**, 64, 202-204	1.2	1
48	Two cases of primary malignant melanoma of the esophagus. *Skin Cancer*, **2017**, 32, 6-11	0	
47	Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer. *International Journal of Cancer*, **2016**, 138, 1281-9	7.5	10
46	High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. *Oncotarget*, **2016**, 7, 3847-56	3.3	49
45	Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma. *Cancer Research*, **2015**, 75, 4188-97	10.1	12
44	Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma. *Cancer Science*, **2015**, 106, 102-7	6.9	7
43	Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma. *Oncology Reports*, **2014**, 31, 1109-15	3.5	10
42	Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer. *Pancreas*, **2014**, 43, 1093-100	2.6	9
41	Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. *Journal of Thoracic Oncology*, **2014**, 9, 775-83	8.9	34

40	Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. *Oncotarget*, **2014**, 5, 4920-8	3.3	40
39	Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. *Oncogene*, **2013**, 32, 4427-35	9.2	20
38	The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. *International Journal of Cancer*, **2013**, 133, 505-13	7.5	25
37	EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. *Cancer Research*, **2013**, 73, 2428-34	10.1	126
36	Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer. *Cancer Science*, **2013**, 104, 1640-6	6.9	16
35	mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. *PLoS ONE*, **2013**, 8, e62104	3.7	25
34	Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. *PLoS ONE*, **2013**, 8, e84700	3.7	38
33	Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency. *JOP: Journal of the Pancreas*, **2013**, 14, 515-20	1.2	2
32	Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands. *Cancer Science*, **2012**, 103, 1189-94	6.9	55
31	Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. *American Journal of Pathology*, **2012**, 181, 1034-43	5.8	45
30	Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. *Molecular Cancer Therapeutics*, **2012**, 11, 2149-57	6.1	73
29	Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. *Clinical Cancer Research*, **2012**, 18, 3592-602	12.9	93
28	Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. *Clinical Cancer Research*, **2012**, 18, 1663-71	12.9	71
27	Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. *Journal of Thoracic Oncology*, **2012**, 7, 272-80	8.9	35
26	Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. *Journal of Thoracic Oncology*, **2012**, 7, 1078-85	8.9	28
25	Abstract B21: E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells. *Clinical Cancer Research*, **2012**, 18, B21-B21	12.9	
24	Abstract PR7: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells. *Clinical Cancer Research*, **2012**, 18, PR7-PR7	12.9	4
23	Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. *American Journal of Pathology*, **2011**, 179, 1483-93	5.8	42

22	Antiangiogenic therapies for malignant pleural mesothelioma. *Frontiers in Bioscience - Landmark*, **2011**, 16, 740-8	2.8	5
21	Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. *Cancer Science*, **2011**, 102, 2157-63	6.9	24
20	The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. *Clinical Cancer Research*, **2011**, 17, 3619-30	12.9	43
19	Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. *Journal of Thoracic Oncology*, **2011**, 6, 2011-7	8.9	176
18	E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor. *Molecular Cancer Therapeutics*, **2011**, 10, 1218-28	6.1	13
17	Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. *Clinical Cancer Research*, **2011**, 17, 2260-9	12.9	89
16	HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. *Current Signal Transduction Therapy*, **2011**, 6, 228-233	0.8	2
15	The role of percutaneous needle biopsy in differentiation of renal tumors. *Japanese Journal of Clinical Oncology*, **2010**, 40, 1081-6	2.8	2
14	Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. *Clinical Cancer Research*, **2010**, 16, 174-83	12.9	85
13	Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib. *International Journal of Clinical Oncology*, **2010**, 15, 638-41	4.2	5
12	Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice. *Molecular Cancer Therapeutics*, **2009**, 8, 119-26	6.1	18
11	Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. *Clinical Cancer Research*, **2009**, 15, 6630-8	12.9	210
10	Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis. *International Journal of Clinical Oncology*, **2009**, 14, 468-72	4.2	5
9	E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. *Clinical Cancer Research*, **2009**, 15, 7229-37	12.9	50
8	Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy. *Internal Medicine*, **2009**, 48, 1651-6	1.1	1
7	A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice. *Oncology Research*, **2009**, 17, 581-91	4.8	13
6	Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2. *Cancer Science*, **2008**, 99, 1603-10	6.9	19
5	Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. *Cancer Letters*, **2008**, 265, 55-66	9.9	22

4	Thioredoxin-1 protects against hyperoxia-induced apoptosis in cells of the alveolar walls. *Pulmonary Pharmacology and Therapeutics*, **2007**, 20, 650-9	3.5	29
3	Overexpression of manganese superoxide dismutase by N-acetylcysteine in hyperoxic lung injury. *Respiratory Medicine*, **2007**, 101, 800-7	4.6	46
2	A novel potent inhibitor of inducible nitric oxide synthase, ONO-1714, reduces hyperoxic lung injury in mice. *Respiratory Medicine*, **2007**, 101, 793-9	4.6	9
1	Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer. *Cancer Chemotherapy and Pharmacology*, **2006**, 58, 735-41	3.5	8